Search results summary
From Health Canada
Search criteria
- Status: Select all
- AIG: 0151381001
Search results
Status | DIN | Company | Product | Class | PM See footnote1 | Schedule | # See footnote2 | A.I. name See footnote3 | Strength |
---|---|---|---|---|---|---|---|---|---|
Marketed | 02522160 | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | ABEVMY | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Marketed | 02522160 | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | ABEVMY | Human | Yes | Prescription | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Marketed | 02522179 | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | ABEVMY | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02522179 | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | ABEVMY | Human | Yes | Prescription | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02270994 | HOFFMANN-LA ROCHE LIMITED | AVASTIN | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 25 MG / ML |
Marketed | 02270994 | HOFFMANN-LA ROCHE LIMITED | AVASTIN | Human | Yes | Prescription | 1 | BEVACIZUMAB | 25 MG / ML |
Marketed | 02522829 | SAMSUNG BIOEPIS CO., LTD | AYBINTIO | Human | Yes | Prescription Recommended | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02522829 | SAMSUNG BIOEPIS CO., LTD | AYBINTIO | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02522837 | SAMSUNG BIOEPIS CO., LTD | AYBINTIO | Human | Yes | Prescription Recommended | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Marketed | 02522837 | SAMSUNG BIOEPIS CO., LTD | AYBINTIO | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Marketed | 02520729 | APOTEX INC | BAMBEVI | Human | Yes | Prescription | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02520729 | APOTEX INC | BAMBEVI | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02520737 | APOTEX INC | BAMBEVI | Human | Yes | Prescription | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Marketed | 02520737 | APOTEX INC | BAMBEVI | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Marketed | 02470748 | AMGEN CANADA INC | MVASI | Human | Yes | Prescription | 1 | BEVACIZUMAB | 25 MG / ML |
Marketed | 02470748 | AMGEN CANADA INC | MVASI | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 25 MG / ML |
Marketed | 02470756 | AMGEN CANADA INC | MVASI | Human | Yes | Prescription | 1 | BEVACIZUMAB | 25 MG / ML |
Marketed | 02470756 | AMGEN CANADA INC | MVASI | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 25 MG / ML |
Marketed | 02534177 | CELLTRION INC. | VEGZELMA | Human | Yes | Prescription | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02534177 | CELLTRION INC. | VEGZELMA | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02534185 | CELLTRION INC. | VEGZELMA | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Marketed | 02534185 | CELLTRION INC. | VEGZELMA | Human | Yes | Prescription | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Marketed | 02489430 | PFIZER CANADA ULC | ZIRABEV | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02489430 | PFIZER CANADA ULC | ZIRABEV | Human | Yes | Prescription | 1 | BEVACIZUMAB | 100 MG / 4 ML |
Marketed | 02489449 | PFIZER CANADA ULC | ZIRABEV | Human | Yes | Schedule D | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Marketed | 02489449 | PFIZER CANADA ULC | ZIRABEV | Human | Yes | Prescription | 1 | BEVACIZUMAB | 400 MG / 16 ML |
Application information
Related information
Contact us
Version 4.0.3